Anebulo: Phase 2 data show ANEB-001 reduces THC effects; cash $16M runway into 2024

Anebulo Pharmaceuticals, Inc.

Preliminary data: single 10 mg ANEB-001 reversed key psychotropic effects of 30 mg THC, including feeling high and body sway.
Delayed dosing of ANEB-001 (1 hour after THC) rapidly reversed pre-existing effects.
Full PK, PD, and safety data expected by end of 1Q2023; FDA End of Phase 2A meeting targeted H1 2023.
Cash of $16M as of Dec 31, 2022 provides runway into 2024.
No serious adverse events; 134 subjects enrolled in Parts A and B.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.